Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review-Reference-Cited by-同舟云学术

Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review

Published:2022-10 Issue:10 Volume:40 Page:413-423
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Padua Tiago Costa de^ORCID,Moschini Marco,Martini Alberto,Pederzoli Filippo,Nocera Luigi,Marandino Laura,Raggi Daniele,Briganti Alberto,Montorsi Francesco,Necchi Andrea

Funder

European Society for Medical Oncology

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference41 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000

3. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up;Fradet;Ann Oncol,2019

4. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma;Powles;N Engl J Med,2020

5. Erdafitinib in locally advanced or metastatic urothelial carcinoma;Loriot;N Engl J Med,2019

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ARNTL2 facilitates bladder cancer progression through potentiating ENO1-mediated glycolysis in a SLC31A1-independent and -dependent manner;Life Sciences;2024-10

2. Disitamab vedotin (RC48) long-term regimen in a post-nephroureterectomy patient with metastases: a case report;Frontiers in Oncology;2024-09-13

3. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database;Frontiers in Immunology;2024-08-20

4. Efficacy and safety of antibody–drug conjugates in the treatment of urothelial cell carcinoma: a systematic review and meta-analysis of prospective clinical trials;Frontiers in Pharmacology;2024-06-12

5. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions;Biomedicine & Pharmacotherapy;2024-05